Sun Pharmaceutical Industries Ltd., India biggest drugmaker by market value, said the company and its subsidiaries settled a lawsuit with MedImmune Inc. on a generic version of the cancer drug Ethyol.
MedImmune granted Sun a license to certain patents allowing the Indian company to continue to sell the generic version in the U.S., the Mumbai-based company said in a statement to the Bombay Stock Exchange today.
“The settlement resolves the entirety of the litigations between the parties,” the statement said.
Sun fell 0.1 percent to 1173.25 rupees as of 10:14 a.m. in Mumbai trading. It rose as much as 2.2 percent earlier today.
The units in the settlement include Caraco Pharmaceutical Laboratories Ltd., 76 percent owned by Sun.
